Phase 1 Huntington’s Disease Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
Huntington’s Disease
Alnylam Pharmaceuticals66 enrolled19 locationsNCT06585449
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
Huntington’s Disease
Hoffmann-La Roche40 enrolled3 locationsNCT07246941
Completed
Phase 1
An Open-Label, Crossover, Relative Bioavailability Study Comparing Tablet and Capsule Formulations of SKY-0515 in Healthy Volunteers
Huntington’s Disease
Skyhawk Therapeutics, Inc.16 enrolled1 locationACTRN12625000082404
Completed
Phase 1
A Phase I Randomised, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect of Food on the Bioavailability of SKY-0515 in Healthy Volunteers and Patients with Huntington’s Disease
Huntington’s Disease
Skyhawk Therapeutics, Inc50 enrolled4 locationsACTRN12624000602527